On Monday, Soleno Therapeutics Inc (NASDAQ: SLNO) was 3.20% up from the session before settling in for the closing price of $67.48. A 52-week range for SLNO has been $36.61 – $74.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 39.57%. With a float of $35.80 million, this company’s outstanding shares have now reached $45.70 million.
Let’s determine the extent of company efficiency that accounts for 92 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Soleno Therapeutics Inc (SLNO) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Soleno Therapeutics Inc stocks. The insider ownership of Soleno Therapeutics Inc is 21.94%, while institutional ownership is 90.92%. The most recent insider transaction that took place on Apr 01 ’25, was worth 265,156. In this transaction an insider of this company sold 3,782 shares at a rate of $70.11, taking the stock ownership to the 27,036 shares. Before that another transaction happened on Apr 01 ’25, when Company’s Officer proposed sale 3,782 for $70.11, making the entire transaction worth $265,156.
Soleno Therapeutics Inc (SLNO) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 39.57% per share during the next fiscal year.
Soleno Therapeutics Inc (NASDAQ: SLNO) Trading Performance Indicators
You can see what Soleno Therapeutics Inc (SLNO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 15.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.26, a number that is poised to hit -0.89 in the next quarter and is forecasted to reach 0.18 in one year’s time.
Technical Analysis of Soleno Therapeutics Inc (SLNO)
Looking closely at Soleno Therapeutics Inc (NASDAQ: SLNO), its last 5-days average volume was 1.59 million, which is a jump from its year-to-date volume of 1.0 million. As of the previous 9 days, the stock’s Stochastic %D was 83.51%. Additionally, its Average True Range was 4.57.
During the past 100 days, Soleno Therapeutics Inc’s (SLNO) raw stochastic average was set at 86.58%, which indicates a significant increase from 83.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 142.69% in the past 14 days, which was higher than the 72.40% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $51.60, while its 200-day Moving Average is $49.68. However, in the short run, Soleno Therapeutics Inc’s stock first resistance to watch stands at $71.74. Second resistance stands at $73.84. The third major resistance level sits at $77.71. If the price goes on to break the first support level at $65.77, it is likely to go to the next support level at $61.90. Now, if the price goes above the second support level, the third support stands at $59.80.
Soleno Therapeutics Inc (NASDAQ: SLNO) Key Stats
There are 45,857K outstanding shares of the company, which has a market capitalization of 3.19 billion. As of now, sales total 0 K while income totals -175,850 K. Its latest quarter income was 0 K while its last quarter net income were -55,980 K.
